CD8+ Cells, UC San Diego School of Medicine (IMAGE)
Caption
The combination therapy with TLR agonist and anti-PD-1 agent activates CD8+ T cells (red) in the tumors.
Credit
UC San Diego Health
Usage Restrictions
use photo credit as indicated
License
Licensed content